Autoimmune Hemolytic Anemia and Spontaneous Pneumothorax as Initial Manifestations of Common Variable Immunodeficiency Complicated with Granulomatous–Lymphocytic Interstitial Lung Disease
Abstract
Common variable immunodeficiency (CVID) is the most common antibody deficiency in adults and is frequently associated with autoimmune conditions. One such condition is autoimmune hemolytic anemia (AIHA), an acquired blood disorder that can be the initial manifestation of CVID. Additionally, patients may develop granulomatous and lymphoproliferative lung disease (GLILD), a serious complication that worsens prognosis and requires early recognition. We describe a 25-year-old man with AIHA who had a severe hemolytic crisis and persistent anemia despite optimal immunomodulatory therapy. Infectious diseases, other autoimmune disorders and neoplasms were ruled out. In further studies, marked hypogammaglobulinemia of IgG, IgA, IgM and IgE was documented, confirming the diagnosis of CVID as the underlying cause of his refractory AIHA. During hospitalization, the patient developed a spontaneous pneumothorax with associated pulmonary micronodules, raising a strong suspicion of GLILD. This case illustrates that CVID may initially present as apparently isolated AIHA and remain unrecognized until serious complications emerge. Measurement of serum immunoglobulin levels should be considered in patients with atypical or treatment-refractory AIHA, recurrent infections, or accompanying lymphoproliferative features, as early recognition of CVID enables timely IVIG replacement and monitoring for associated complications.
2. Salzer U, Warnatz K, Peter H. Common variable immunodeficiency - an update. Arthritis Res Ther. 2012;14(5):223.
3. Di Renzo M, Pasqui AL, Auteri A. Common variable immunodeficiency: A review. Clin Exp Med. 2004;3:211–217.
4. Cunningham-Rundles C. Common variable immune deficiency: case studies. Hematology Am Soc Hematol Educ Program. 2019 ;2019(1):449–456.
5. Hurst JR, Abbas SH, Bintalib HM, et al. Granulomatous–lymphocytic interstitial lung disease: an international research prioritisation. ERJ Open Res. 2021;7(4):00467–02021.
6. Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650–1657.
7. Hurst JR, Verma N, Lowe D, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2017;5(4):938–945.
8. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763–1770.
9. Abbott JK, Gelfand EW. Common Variable Immunodeficiency. Immunol Allergy Clin North Am. 2015;35(4):637–658.
10. Cunningham-Rundles C, Maglione PJ. Common variable immunodeficiency. J Allergy Clin Immunol. 2012;129(5):1425-1426.e3.
11. Settipane G, Pudupakkam R, McGowan J. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol. 1978;62(3):162–166.
12. Sève P, Bourdillon L, Sarrot-Reynauld F, et al. Autoimmune Hemolytic Anemia and Common Variable Immunodeficiency. Medicine (Baltimore). 2008; 87(3):177-184.
13. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286.
14. Cinetto F, Scarpa R, Neri R, et al. Granulomatous-Lymphocytic interstitial lung disease (GLILD) in CVID: A case-control single center retrospective study. Eur Respir J. 2019 :54(Suppl 63) :PA1955.
15. Lamers OAC, Smits BM, Leavis HL, et al. Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review. Front Immunol. 2021;12:606099.
16. Meerburg JJ, Hartmann IJC, Goldacker S, et al. Analysis of Granulomatous Lymphocytic Interstitial Lung Disease Using Two Scoring Systems for Computed Tomography Scans—A Retrospective Cohort Study. Front Immunol. 2020;11:589148.
17. Ruiz-Alcaraz S, Gayá García-Manso I, Marco-De La Calle FM, et al. Granulomatous lymphocytic interstitial lung disease: Description of a series of 9 cases. Med Clin (Barc). 2021;156(7):344-348.
18. Strunz PP, Fröhlich M, Gernert M, et al. Rituximab for the Treatment of Common Variable Immunodeficiency (CVID) with Pulmonary and Central Nervous System Involvement. Open Rheumatol J. 2021;15(1):9–15.
19. Stefanidis K, Rafailidis V, Karafotias I, et al. Pneumomediastinum complicating granulomatous–lymphocytic interstitial lung disease in common variable immunodeficiency. BMJ Case Rep. 2020;13(7):e235557.
20. Smits B, Goldacker S, Seneviratne S, et al. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease. Allergy Clin Immunol. 2023;152(2):528–537.
| Files | ||
| Issue | Vol 20 No 3 (2026) | |
| Section | Case Report(s) | |
| Keywords | ||
| Common variable immunodeficiency; Hemolytic anemia; Granulomatous lymphocytic interstitial lung disease; Autoimmune extra-pulmonary manifestations; Hematologic disease; Primary immunodeficiency | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |

